Synthetic self‐adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy

Documenti analoghi

• Deleting SUV39H1 in CAR‐T cells epigenetically enhances the antitumor function
  di: Yuning Wang, et al.
  Pubblicazione: (2024)
• 5,7,4′‐Trimethoxyflavone triggers cancer cell PD‐L1 ubiquitin–proteasome degradation and facilitates antitumor immunity by targeting HRD1
  di: Jianhua Xia, et al.
  Pubblicazione: (2024)
• Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
  di: Xiyuan Wang, et al.
  Pubblicazione: (2024)
• Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges
  di: Yan Zhang, et al.
  Pubblicazione: (2024)
• Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy
  di: Fei Wang, et al.
  Pubblicazione: (2024)